Affordable Access

Access to the full text

Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy

Authors
  • Loya, Joshua1
  • Zhang, Charlie2
  • Cox, Emily3
  • Achrol, Achal S4
  • Kesari, Santosh4
  • 1 Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI 48202, USA
  • 2 Buffalo School of Medicine, State University of New York, Buffalo, NY 14202, USA
  • 3 Providence Medical Research Center, Spokane, WA 99204, USA
  • 4 John Wayne Cancer Institute, Pacific Neuroscience Institute, Santa Monica, CA 90404, USA
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Nov 21, 2019
Volume
8
Issue
3
Identifiers
DOI: 10.2217/cns-2019-0002
PMID: 31747784
PMCID: PMC6880300
Source
PubMed Central
Keywords
License
Green

Abstract

Management of high-grade gliomas (HGGs) remains a complex challenge with an overall poor prognosis despite aggressive multimodal treatment. New translational research has focused on maximizing tumor cell eradication through improved tumor cell targeting while minimizing collateral systemic side effects. In particular, biological intratumoral therapies have been the focus of novel translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two part review will provide an overview of biological intratumoral therapies that have been evaluated in human clinical trials in HGGs, and summarize key advances and remaining challenges in the development of these therapies as a potential new paradigm in the management of HGGs. Part II discusses vector-based therapies, cell-based therapies and radioimmunotherapy.

Report this publication

Statistics

Seen <100 times